1. A patient maintained on high-dose chlorpromazine is troubled by heavy sedation, dry mouth, and dizziness on standing, but has had no movement-related problems. The team switches the patient to haloperidol titrated to the same level of D2 receptor occupancy. Integrating what determines antipsychotic efficacy with what determines the side-effect profile, what is the most likely net result of this switch?
A) Both the antipsychotic effect and all side effects will diminish, because haloperidol is given at a far smaller dose
B) The antipsychotic effect should be comparable at equivalent occupancy, the sedation, dry mouth, and orthostatic dizziness should improve, but the risk of extrapyramidal symptoms (movement side effects) should rise
C) The antipsychotic effect will be markedly weaker, because the smaller haloperidol dose cannot match chlorpromazine's efficacy
D) The sedation and anticholinergic effects will worsen, because haloperidol has greater histamine and muscarinic blockade than chlorpromazine
E) The patient's risk of extrapyramidal symptoms will fall, because high-potency agents are intrinsically gentler on the motor system
ANSWER: B
Rationale:
At equivalent D2 occupancy the two agents produce comparable antipsychotic effect, because efficacy tracks occupancy rather than dose. The side-effect change is driven by the receptor profile at the doses required: chlorpromazine's troublesome sedation, dry mouth, and orthostasis come from H1, M1, and alpha-1 blockade at its large doses, so a switch to haloperidol — which reaches the same occupancy at small doses with little off-target activity — should relieve those effects while raising extrapyramidal risk, since haloperidol's D2 selectivity and tight binding carry the highest EPS liability in the class.
Option A: Option A is incorrect because efficacy is preserved at equal occupancy and EPS risk rises rather than falls.
Option C: Option C is incorrect because a small dose of a high-potency agent is fully effective once therapeutic occupancy is reached.
Option D: Option D is incorrect because haloperidol has less, not more, H1 and M1 blockade than chlorpromazine.
Option E: Option E is incorrect because high-potency D2-selective agents carry greater, not lesser, extrapyramidal risk at equivalent antipsychotic effect.
2. A patient started on a standard 5 mg daily dose of haloperidol develops marked rigidity and tremor within the first week. Genotyping later shows the patient is a poor metabolizer at the liver enzyme CYP2D6, which clears haloperidol. Integrating the pharmacokinetic finding with the relationship between D2 occupancy and extrapyramidal effects, which interpretation and action are most appropriate?
A) The poor-metabolizer status has driven plasma haloperidol roughly two to three times higher than expected, pushing D2 occupancy above the therapeutic window into the range where extrapyramidal symptoms appear without added benefit, so the dose should be reduced rather than increased
B) The rigidity reflects too little D2 occupancy, so the dose should be increased to push past the threshold for benefit
C) The genotype is irrelevant, because CYP2D6 does not metabolize haloperidol; only smoking-induced enzymes affect this drug
D) The patient should be switched to thioridazine, which is unaffected by metabolizer status and carries no comparable risk
E) The finding indicates accelerated clearance, so the half-life is shortened and the symptoms must be unrelated to drug level
ANSWER: A
Rationale:
Poor CYP2D6 metabolism slows haloperidol clearance, raising plasma concentrations roughly two to three times above those of extensive metabolizers at the same dose; this pushes D2 occupancy above the therapeutic 65 to 80 percent window into the range where extrapyramidal symptoms emerge without additional antipsychotic benefit. The integrated inference is that the toxicity is concentration-driven, so the correct action is dose reduction, not escalation.
Option B: Option B is incorrect because the rigidity reflects excessive, not insufficient, occupancy, so raising the dose would worsen it.
Option C: Option C is incorrect because CYP2D6 is specifically relevant to haloperidol metabolism.
Option D: Option D is incorrect because thioridazine carries the worst cardiac risk in the class and is not an appropriate reflexive substitute.
Option E: Option E is incorrect because poor-metabolizer status slows clearance and prolongs exposure, so the symptoms are directly related to the elevated drug level.
3. A patient who smokes heavily has been stable for years on chlorpromazine as an outpatient. The patient is admitted to a smoke-free inpatient psychiatric unit and stops smoking abruptly on admission. Cigarette smoke induces the liver enzyme CYP1A2 that clears chlorpromazine. Integrating the enzyme-induction principle with the change in smoking status, what should the team anticipate and do?
A) Nothing changes, because once a patient is stable the plasma level is fixed regardless of smoking
B) Plasma chlorpromazine will fall sharply on the unit, so the dose should be increased to prevent relapse
C) Loss of the smoking-related enzyme induction will slow chlorpromazine metabolism and raise plasma levels over the following days, so the team should monitor for emerging sedation and anticholinergic toxicity and consider a proactive dose reduction
D) The interaction matters only for high-potency agents such as haloperidol, so chlorpromazine levels are unaffected by stopping smoking
E) Stopping smoking will speed renal elimination of chlorpromazine, lowering its level and requiring a dose increase
ANSWER: C
Rationale:
Heavy smoking induces CYP1A2, keeping chlorpromazine levels relatively low; when the patient stops smoking on a smoke-free unit, the induction is lost over several days, metabolism slows, and plasma chlorpromazine rises. The integrated anticipation is therefore rising levels with new sedation and anticholinergic toxicity, and the appropriate action is to monitor and consider a proactive dose reduction.
Option A: Option A is incorrect because steady-state levels depend on ongoing enzyme activity, which the smoking change alters.
Option B: Option B is incorrect because stopping the inducer raises rather than lowers levels, so increasing the dose would compound toxicity.
Option D: Option D is incorrect because chlorpromazine is in fact a CYP1A2 substrate and is directly affected; the interaction is even greater for clozapine and olanzapine.
Option E: Option E is incorrect because the interaction operates through hepatic enzyme induction, not renal elimination, and levels rise rather than fall.
4. A trainee proposes giving a standing anticholinergic agent to every patient on a first-generation antipsychotic, reasoning that since anticholinergics relieve acute dystonia they should help all drug-induced movement problems. Integrating the differing mechanisms of acute dystonia and tardive dyskinesia, why is this reasoning flawed?
A) Anticholinergics relieve both dystonia and tardive dyskinesia equally, so the only problem is the added cost
B) Acute dystonia and tardive dyskinesia share an identical mechanism, so a single agent should treat both
C) Anticholinergics worsen acute dystonia and relieve tardive dyskinesia, the reverse of what the trainee assumes
D) Acute dystonia reflects a relative cholinergic excess that an anticholinergic corrects, whereas tardive dyskinesia reflects dopamine receptor supersensitivity, a different mechanism that anticholinergics do not help and can actually worsen
E) Neither syndrome responds to anticholinergics, so the proposal has no pharmacological basis at all
ANSWER: D
Rationale:
Acute dystonia arises when dopamine blockade unmasks a relative cholinergic excess in the basal ganglia, so an anticholinergic restores balance and relieves it. Tardive dyskinesia, by contrast, arises from dopamine receptor supersensitivity that develops during chronic blockade — a fundamentally different mechanism — and anticholinergics do not help it and can worsen it. The two syndromes therefore cannot be managed with one blanket agent, which is the flaw in the trainee's reasoning.
Option A: Option A is incorrect because the agents do not relieve both equally; they can aggravate tardive dyskinesia.
Option B: Option B is incorrect because the two syndromes have distinct, even opposing, mechanisms.
Option C: Option C is incorrect because it inverts reality: anticholinergics relieve dystonia and worsen tardive dyskinesia, not the reverse.
Option E: Option E is incorrect because anticholinergics are genuinely effective for acute dystonia, so the proposal is not without any basis — it is simply wrong to generalize it.
5. A patient with adherence difficulties is being considered for haloperidol decanoate, the long-acting injectable (depot) form. The patient previously developed severe akathisia (motor restlessness) on oral haloperidol at a dose roughly equivalent to the planned monthly depot dose. Integrating depot pharmacokinetics with the principle of establishing oral tolerability first, what is the soundest approach?
A) Do not proceed directly to the equivalent depot dose, because the depot delivers the same receptor occupancy with a long washout, so the akathisia would likely recur and resolve only slowly; either address the akathisia and confirm oral tolerability first or choose a different long-acting agent
B) Proceed with the equivalent depot dose, because the depot changes the receptor-binding profile and therefore will not reproduce the akathisia
C) Proceed with a markedly higher depot dose, because depot formulations require supratherapeutic loading to overcome slow absorption
D) Proceed immediately, because any adverse effect from a depot injection can be reversed within hours if it appears
E) Avoid all long-acting injectables permanently, because prior akathisia is an absolute contraindication to any depot antipsychotic
ANSWER: A
Rationale:
A depot formulation changes only the delivery kinetics, not the receptor-binding profile, so a patient who experienced akathisia on oral haloperidol at an equivalent dose will encounter the same EPS-prone occupancy on haloperidol decanoate. Because the depot reaches steady state slowly and has a long washout, any recurrent akathisia would resolve only slowly, which is why sound practice is to establish oral tolerability first or select a different long-acting agent.
Option B: Option B is incorrect because the depot does not alter the receptor profile and would reproduce the akathisia.
Option C: Option C is incorrect because supratherapeutic loading would increase, not reduce, the adverse-effect risk.
Option D: Option D is incorrect because depot adverse effects are slow to resolve over weeks, not reversible within hours.
Option E: Option E is incorrect because prior akathisia is a caution prompting dose optimization or agent selection, not an absolute contraindication to every depot antipsychotic.
6. Several days into haloperidol treatment, a patient becomes visibly restless and paces constantly. The covering clinician records "worsening agitation" and raises the haloperidol dose, after which the restlessness intensifies. Integrating the recognition problem with the correct management sequence, which course of action is most appropriate now?
A) Continue raising the haloperidol dose, since escalating restlessness signals undertreated psychosis
B) Add a standing anticholinergic, which is the most evidence-supported treatment for this syndrome
C) Diagnose tardive dyskinesia and begin a VMAT2 inhibitor without changing the haloperidol
D) Conclude the patient has neuroleptic malignant syndrome and stop all treatment pending dantrolene
E) Recognize that this is akathisia being worsened by the dose increase, reverse the escalation by reducing the dose where feasible, and treat with propranolol, the most evidence-supported agent for the subjective restlessness
ANSWER: E
Rationale:
Motor restlessness with an urge to move that appears within days of starting an antipsychotic is akathisia; because it is itself driven by the dopamine blockade, mistaking it for agitation and raising the dose worsens it, which is exactly the trajectory described. The integrated correct sequence is to recognize the syndrome, reverse the escalation by reducing the dose where feasible, and use propranolol, the most evidence-supported agent for the subjective restlessness.
Option A: Option A is incorrect because further escalation worsens akathisia rather than treating psychosis.
Option B: Option B is incorrect because anticholinergics are less consistently effective for akathisia than for dystonia or parkinsonism and are not first-line here.
Option C: Option C is incorrect because tardive dyskinesia appears after months to years and consists of orofacial movements, not early restlessness.
Option D: Option D is incorrect because there is no fever, rigidity, or autonomic instability to indicate neuroleptic malignant syndrome.
7. A patient develops neuroleptic malignant syndrome after a rapid haloperidol dose escalation. Integrating the proposed mechanism of the syndrome with the rationale for its specific pharmacological treatments, which explanation best links the management to the underlying pathophysiology?
A) The syndrome is caused by excess dopamine, so management centers on adding more D2 blockade to suppress it
B) The syndrome is an allergic reaction, so the mainstay is high-dose antihistamines with no role for dopaminergic agents
C) The syndrome is thought to result from rapid, extensive D2 blockade, so management combines stopping the antipsychotic and supportive cooling and hydration with dantrolene to reduce the rigidity and hyperthermia and a dopamine agonist such as bromocriptine or amantadine to restore central dopaminergic tone
D) The syndrome is purely peripheral muscle disease, so only dantrolene is needed and central dopaminergic agents are irrelevant
E) The syndrome reflects serotonin excess, so a serotonin antagonist is the definitive and sufficient treatment
ANSWER: C
Rationale:
Neuroleptic malignant syndrome is thought to result from rapid, extensive D2 blockade in the nigrostriatal pathway and hypothalamus, producing rigidity, impaired heat dissipation, and disrupted thermoregulation. The treatments map directly onto this mechanism: discontinue the antipsychotic and give supportive cooling and hydration, use dantrolene to reduce the rigidity and hyperthermia, and use a dopamine agonist such as bromocriptine or amantadine to restore the central dopaminergic tone that the blockade removed.
Option A: Option A is incorrect because the syndrome arises from too much D2 blockade, not excess dopamine, so adding blockade would worsen it.
Option B: Option B is incorrect because it is not an allergic reaction and antihistamines are not the mainstay.
Option D: Option D is incorrect because the syndrome has a central dopaminergic basis, so dopaminergic restoration is part of management, not irrelevant.
Option E: Option E is incorrect because, although there may be a serotonergic contribution and clinical overlap with serotonin syndrome, a serotonin antagonist is not the definitive treatment for neuroleptic malignant syndrome.
8. A patient on a high dose of haloperidol has a very high measured plasma concentration yet shows a poorer antipsychotic response than expected. Reduced haloperidol, the primary active metabolite, has partial D2 agonist properties. Integrating this metabolite pharmacology with the dose-response relationship, which interpretation best accounts for the paradox?
A) The high concentration proves the patient is non-adherent, since adherent patients never reach such levels
B) At very high concentrations, accumulation of the partial-agonist metabolite reduced haloperidol can blunt net D2 antagonism, offering a pharmacological explanation for why an extremely high haloperidol level can paradoxically reduce antipsychotic response rather than improve it
C) The high concentration guarantees a strong response, so the reported poor response must be a charting error
D) The metabolite is pharmacologically inert, so plasma levels and response are unrelated
E) The poor response means the dose is still too low, so the haloperidol dose should be pushed higher
ANSWER: B
Rationale:
Reduced haloperidol, the primary active metabolite, has partial D2 agonist properties; at very high parent-drug concentrations its accumulation can blunt the net D2 antagonism, which provides a pharmacological explanation for the clinical observation that extremely high haloperidol concentrations can paradoxically reduce rather than improve antipsychotic response.
Option A: Option A is incorrect because a very high level is not evidence of non-adherence; if anything it indicates substantial drug exposure.
Option C: Option C is incorrect because a high concentration does not guarantee a strong response, which is precisely the paradox being explained.
Option D: Option D is incorrect because the metabolite is pharmacologically active, not inert.
Option E: Option E is incorrect because pushing the dose still higher would further increase the partial-agonist metabolite and is not the indicated response to this paradox.
9. A patient maintained on thioridazine, which blocks the cardiac hERG potassium channel and prolongs the QTc interval, develops an infection requiring a fluoroquinolone antibiotic that also prolongs the QTc, and laboratory testing shows a low serum potassium. Integrating the additive cardiac effects with the electrolyte status, which management is safest?
A) Recognize that the thioridazine, the QTc-prolonging antibiotic, and the hypokalemia together compound the risk of torsades de pointes; the safest approach is to switch to a different antipsychotic for the course of the antibiotic and correct the potassium, rather than continuing the combination
B) Continue both drugs unchanged, because QTc-prolonging effects from different drug classes do not add together
C) Continue both drugs and rely on the hypokalemia to shorten the QTc and offset the risk
D) Double the thioridazine dose to ensure antipsychotic coverage during the acute illness, deferring any cardiac concern
E) Stop the antibiotic and leave the infection untreated, since the antipsychotic must never be interrupted
ANSWER: A
Rationale:
Thioridazine's hERG-channel blockade is additive with other QTc-prolonging drugs such as fluoroquinolones, and hypokalemia independently lowers the threshold for torsades de pointes, so the three factors compound the arrhythmia risk. The safest integrated approach is to switch to a different antipsychotic for the duration of the QTc-prolonging antibiotic and correct the potassium, rather than manage the dangerous combination.
Option B: Option B is incorrect because QTc-prolonging effects from different drugs are additive, not independent.
Option C: Option C is incorrect because hypokalemia worsens, rather than offsets, the torsades risk.
Option D: Option D is incorrect because doubling thioridazine would increase the QTc and the danger.
Option E: Option E is incorrect because leaving a significant infection untreated is unsafe, and the antipsychotic can be substituted rather than the antibiotic withheld.
10. An older woman with a history of an affective (mood) disorder has been maintained for several years on a high-potency first-generation antipsychotic. She has no movement abnormality yet. Integrating the known risk factors for tardive dyskinesia with the principle that prevention is the most effective strategy, which management plan is most appropriate?
A) Continue the current dose indefinitely without movement assessments, since she has no abnormal movements now
B) Increase the dose preemptively, because higher doses protect against tardive dyskinesia
C) Reassure her that her age and sex lower her risk, so no special monitoring or dose attention is needed
D) Recognize that her age, female sex, affective-disorder history, and cumulative high-potency exposure place her at elevated tardive-dyskinesia risk, and respond by using the lowest effective dose, periodically reassessing whether continued antipsychotic therapy is needed, considering an agent with lower tardive-dyskinesia liability, and monitoring with a standardized movement scale such as the Abnormal Involuntary Movement Scale (AIMS)
E) Stop the antipsychotic abruptly, since discontinuation guarantees that tardive dyskinesia can never develop
ANSWER: D
Rationale:
Older age, female sex, a history of affective disorder, and longer, higher cumulative first-generation exposure all elevate tardive-dyskinesia risk, and because established tardive dyskinesia often persists even after drug discontinuation, prevention is the most effective strategy. The integrated plan is to use the lowest effective dose, periodically reassess the ongoing need for therapy, consider a lower-liability agent, and monitor with a standardized scale such as the AIMS administered at regular intervals.
Option A: Option A is incorrect because the absence of current movements does not remove the risk, and monitoring is precisely what is needed.
Option B: Option B is incorrect because higher cumulative dose increases, not decreases, tardive-dyskinesia risk.
Option C: Option C is incorrect because her age and sex raise rather than lower her risk.
Option E: Option E is incorrect because abrupt discontinuation is not warranted here and does not guarantee prevention, since tardive dyskinesia can emerge or persist around dose reduction.
11. A patient with chronic schizophrenia and significant adherence difficulties has no prominent negative symptoms or cognitive deficits, and cost of care is a real constraint. A large effectiveness trial found that the first-generation agent perphenazine performed comparably to several second-generation agents on all-cause treatment discontinuation. Integrating that finding with this patient's adherence and cost picture, which reasoning best supports drug selection?
A) The trial finding is irrelevant to selection, because second-generation agents are always superior and should be chosen regardless of cost or adherence
B) Because the patient has adherence difficulties, only an oral second-generation agent is appropriate, and first-generation depot options should not be considered
C) The comparable-effectiveness finding makes a first-generation agent a defensible, pharmacoeconomically reasonable choice for a patient without a specific second-generation indication, and the availability of an inexpensive first-generation long-acting injectable such as haloperidol or fluphenazine decanoate can directly address the adherence problem
D) The patient's adherence problem is best solved by lowering the dose of any oral agent, making the choice between classes unimportant
E) The finding proves perphenazine is superior to all second-generation agents, so it must be selected for every patient with schizophrenia
ANSWER: C
Rationale:
The finding that perphenazine performed comparably to several second-generation agents supports using a first-generation agent as a defensible, cost-conscious choice in a patient without a specific indication for a second-generation drug, and the adherence difficulty is directly addressed by an established, inexpensive first-generation long-acting injectable such as haloperidol decanoate or fluphenazine decanoate — integrating effectiveness, cost, and adherence into one selection.
Option A: Option A is incorrect because the trial finding is directly relevant and second-generation superiority is not categorical.
Option B: Option B is incorrect because first-generation depot formulations are exactly suited to adherence problems and should be considered.
Option D: Option D is incorrect because simply lowering an oral dose does not solve non-adherence and the class choice does matter here.
Option E: Option E is incorrect because the finding showed comparable, not superior, effectiveness and does not mandate perphenazine for everyone.
12. A premenopausal woman on long-term first-generation antipsychotic therapy reports amenorrhea and galactorrhea. First-generation agents raise prolactin by blocking dopamine at the tuberoinfundibular pathway, where dopamine normally restrains prolactin release. Integrating this mechanism with its long-term consequences, which concern and action are most appropriate?
A) The symptoms are unrelated to the antipsychotic, since these agents lower rather than raise prolactin
B) Hyperprolactinemia from these agents has no long-term skeletal consequences, so only the cosmetic symptoms need attention
C) The prolactin elevation is beneficial and protective for bone, so no monitoring is warranted
D) The amenorrhea reflects accelerated metabolism of the drug and will resolve spontaneously without any evaluation
E) Sustained hyperprolactinemia from tuberoinfundibular D2 blockade can, over many months, reduce bone mineral density and raise fracture risk, particularly in premenopausal women, so prolactin should be checked and the antipsychotic regimen reconsidered in light of that risk
ANSWER: E
Rationale:
First-generation antipsychotics block dopamine at the tuberoinfundibular pathway, removing the normal dopaminergic brake on prolactin and producing hyperprolactinemia with galactorrhea and amenorrhea. Integrating this with its long-term consequence, sustained hyperprolactinemia over many months can reduce bone mineral density and increase fracture risk, an underrecognized concern that is particularly relevant in premenopausal women, so checking prolactin and reconsidering the regimen is appropriate.
Option A: Option A is incorrect because these agents raise, not lower, prolactin, and the symptoms are directly drug-related.
Option B: Option B is incorrect because sustained hyperprolactinemia does carry skeletal consequences beyond the immediate symptoms.
Option C: Option C is incorrect because the elevation is harmful to bone over time, not protective.
Option D: Option D is incorrect because the amenorrhea reflects prolactin elevation from D2 blockade, not accelerated drug metabolism, and warrants evaluation.
13. In an emergency department, a severely agitated antipsychotic-naive young man is managed with the widely used combination of intramuscular haloperidol plus lorazepam (a benzodiazepine) plus diphenhydramine. Integrating the contributions of the three components, which explanation best accounts for why this combination is preferred over haloperidol alone?
A) The three drugs are interchangeable, so the combination offers no advantage beyond using any one of them at a higher dose
B) Haloperidol provides the D2 blockade for the underlying agitation, the benzodiazepine adds faster and more reliable sedation than haloperidol alone, and the diphenhydramine reduces the risk of acute dystonia that is especially high in an antipsychotic-naive young male
C) The benzodiazepine is included only to treat any seizures the haloperidol might cause, and the diphenhydramine is purely for its antihistamine sedation with no protective role
D) The diphenhydramine is given to raise haloperidol plasma levels, and the benzodiazepine is added to prolong the antipsychotic's half-life
E) The combination is preferred solely because three injections are administratively simpler than one, with no pharmacological rationale
ANSWER: B
Rationale:
Each component contributes a distinct, complementary effect: haloperidol supplies the D2 blockade addressing the agitation, the benzodiazepine adds faster and more reliable sedation than haloperidol alone, and diphenhydramine reduces the risk of acute dystonia, which is especially high in an antipsychotic-naive young male — together explaining why the combination outperforms haloperidol monotherapy.
Option A: Option A is incorrect because the drugs are not interchangeable; each plays a different mechanistic role.
Option C: Option C is incorrect because the benzodiazepine is added for rapid sedation, not seizure treatment, and the diphenhydramine has a specific dystonia-prophylaxis role rather than serving only as a sedative.
Option D: Option D is incorrect because diphenhydramine is not given to raise haloperidol levels and the benzodiazepine does not prolong the antipsychotic's half-life.
Option E: Option E is incorrect because the combination rests on a clear pharmacological rationale, not administrative convenience.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.